Literature DB >> 32820363

A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study.

Helena Norberg1,2, Ellinor Bergdahl1, Karin Hellström Ängerud3, Krister Lindmark4.   

Abstract

PURPOSE: To develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients. METHODS AND
RESULTS: The systematic introduction approach is a seven-step procedure: step 1, define a few main criteria; step 2, primary scan patients with the one or two main criteria using computerized medical records/databases/clinical registries; step 3, identify patients applying the other predefined criteria; step 4, evaluate if any examinations/laboratory test updates are required; step 5, summon identified patients to the clinic with an information letter; step 6, discuss treatment with the patient and prescribe if appropriate; and step 7, follow up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. In total, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. This resulted in three final categories: a good approach, role of the information letter, and trust in care.
CONCLUSIONS: The systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient's confidence in healthcare.

Entities:  

Keywords:  Chronic disease management; Healthcare quality improvement; Sacubitril-valsartan; Systematic implementation

Year:  2020        PMID: 32820363     DOI: 10.1007/s00228-020-02979-w

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

Review 2.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2017-04-28       Impact factor: 29.690

Review 3.  Changing Provider Behavior in the Context of Chronic Disease Management: Focus on Clinical Inertia.

Authors:  Kim L Lavoie; Joshua A Rash; Tavis S Campbell
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-09-07       Impact factor: 13.820

Review 4.  Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.

Authors:  Gianluigi Savarese; Juan-Jesus Carrero; Bertram Pitt; Stefan D Anker; Giuseppe M C Rosano; Ulf Dahlström; Lars H Lund
Journal:  Eur J Heart Fail       Date:  2018-03-26       Impact factor: 15.534

5.  Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).

Authors:  Nancy Luo; Gregg C Fonarow; Steven J Lippmann; Xiaojuan Mi; Paul A Heidenreich; Clyde W Yancy; Melissa A Greiner; Bradley G Hammill; N Chantelle Hardy; Stuart J Turner; Warren K Laskey; Lesley H Curtis; Adrian F Hernandez; Robert J Mentz; Emily C O'Brien
Journal:  JACC Heart Fail       Date:  2017-04       Impact factor: 12.035

6.  Age- and sex-related differences in use of guideline-recommended care and mortality among patients with incident heart failure in Denmark.

Authors:  Anne Nakano; Kenneth Egstrup; Marie Louise Svendsen; Inge Schjødt; Lars Jakobsen; Frank Mehnert; Søren Paaske Johnsen
Journal:  Age Ageing       Date:  2016-07-18       Impact factor: 10.668

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

8.  Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.

Authors:  Lindsey R Sangaralingham; S Jeson Sangaralingham; Nilay D Shah; Xiaoxi Yao; Shannon M Dunlay
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

9.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

10.  Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.

Authors:  Anna Jonsson; Helena Norberg; Ellinor Bergdahl; Krister Lindmark
Journal:  Cardiovasc Ther       Date:  2018-08-14       Impact factor: 3.023

View more
  3 in total

1.  Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study.

Authors:  Iréne Jern; Sara Forsell; Helena Norberg
Journal:  BMJ Open       Date:  2022-09-12       Impact factor: 3.006

2.  Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.

Authors:  Federico Guerra; Ernesto Ammendola; Matteo Ziacchi; Vittorio Aspromonte; Pier Luigi Pellegrino; Giuseppe Del Giorno; Gabriele Dell'Era; Lorenzo Pimpini; Francesco Santoro; Roberto Floris; Giulia Stronati; Gerardo Nigro; Pasquale Paolisso; Alessandro Guido; Giampiero Maglia; Natale Daniele Brunetti; Angelo Carbone; Miriam Gravellone; Roberto Antonicelli; Michele Cannone; Michele Accogli; Antonio Dello Russo; Pietro Palmisano
Journal:  Eur J Clin Pharmacol       Date:  2021-07-19       Impact factor: 2.953

3.  Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.

Authors:  Krister Lindmark; Björn Pilebro; Torbjörn Sundström; Per Lindqvist
Journal:  ESC Heart Fail       Date:  2020-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.